Company: SPRB
Filing Date: 2025-12-12
Form Type: 424B3
Source: 0001193125-25-317547
Chunk: 16

Company: SPRUCE BIOSCIENCES, INC.
Filing Date: 2025-12-12
Form: 424B3
Chunk 16
---
 owns a controlling interest in CGP. Mr. Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or to direct the disposition of, the securities held by Citadel CEMF Investments Ltd. The address of Citadel CEMF Investments Ltd. is c/o Citadel Enterprise Americas LLC, 830 Brickell Plaza, Floor 15, Miami, FL 33131.

(5) Consists of (i) 47,276 shares of common stock issuable upon exercise of warrants purchased in a private placement on February 16, 2023, or the 2023 Warrants, held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, or the Master Fund, and (ii) 71,000 shares of common stock issuable upon exercise of Pre-Funded Warrants purchased in the Private Placement by the Master Fund. Such amount does not include 38,000 shares of common stock issuable upon exercise of Pre-Funded Warrants purchased in the Private Placement by the Master Fund. The Pre-Funded Warrants and the 2023 Warrants are subject to a beneficial ownership limitation of 9.99% and 4.99%, respectively, which limitations restrict the Master Fund from exercising that portion of the Pre-Funded Warrants and/or the 2023 Warrants, as applicable, that would result in the Master Fund and its affiliates owning, after exercise, a number of shares of common stock in excess of the applicable beneficial ownership limitation. The securities are directly held by the Master Fund, and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC, or Armistice Capital, as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.

(6) Consists of (i) 10,000 shares of common stock, (ii) 70,000 shares of common stock issued in the Private Placement and (iii) 9,999 shares of common stock issuable upon exercise of the 2023 Warrants, in each case held by Alyeska Master Fund, L.P. The 2023 Warrants are subject to a beneficial ownership limitation of